Cancer Market Trends 2008 - 2012

Publication Date	January 2009
Publisher	URCH Publishing
Product Type	Report
Pages	122
ISBN Number	1905751028
Product Code	URC00018

Buy this product or for assistance call +44 20 7060 7474

PDF £1,100.00$1804 | €1218

PRINT £1,150.00$1886 | €1273

FAX Order above formats by FAX

Summary

The global cancer market has seen a continued period of rapid growth. Global sales for cancer-treating drugs increased by 13.3% in 2007, primarily driven by growth in sales of innovative drugs. Although growth rates for this market will slow due to generic competition, the market is predicted to expand to $103.9 billion by 2012, equivalent to CAGR of 9.4%.

Key findings from this report:

The global cancer market grew to US$66.2 billion in 2007, a year-on-year increase of 13.3%.
This market growth in 2007 was primarily driven by growth of 44.0% in innovatives sales.
There were a total of 21 different cancer therapies generating global sales in excess of US$1 billion in 2007.
The leading company by cancer sales in 2007 was Amgen, with sales of US$11.1 billion.
The global cancer market is forecast to expand to US$103.9 billion in 2012, equivalent to a CAGR of 9.4% over the next 5 years.

This comprehensive report delivers market forecasts and overviews to help inform your pharmaceutical business decision-making.

Features of the report:

Sales forecast for top ten companies providing cancer treatment medicines.
Analysis of leading cancer products likely to loose patent protection in the next ten years.
Sales forecasts to 2012 for the top ten cancer medicines and forecasts by drug class.
Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
Breakdown of the major market trends and business opportunities

Use This Report To:

Benchmark your company's portfolio against market trends and forecasts to plan better for greater profitability.
Identify potential areas of pharmaceutical market growth and opportunities for delivering successful sales growth
Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.

The 122 page publication contains 49 Figures and 43 Tables to help you make sense of the wealth of data. This unique report from URCH Publishing will be of particular use to those involved in:

corporate planning,
sales and marketing,
portfolio management, and,
market forecasting.

Cancer Market Trends 2008 - 2012 is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. The final report chapter outlines future cancer market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cancer market trends.

Content

Summary
- Introduction
- Key disease markets
- Key drug classes
- Key products
- Key companies
- Key trends and opportunities
Chapter 1 Introduction
- Global cancer market
- Report overview
  - Methodology
  - Sources
  - Structure
Chapter 2 Key disease markets
- Key cancer markets
  - Disease burden
  - Cancer incidence
  - Cancer mortality
- Cancer epidemiology
  - Prostate cancer
  - Breast cancer
  - Lung and bronchus cancer
  - Colorectal cancer
  - Urinary bladder cancer
  - Non-Hodgkin's lymphoma
  - Melanoma
  - Kidney and renal pelvis cancer
  - Leukemia
  - Uterine corpus/endometrium (uterus) cancer
- Cancer treatment-related disorders
- Nausea and vomiting
- Hematological disorders
- Other cancer treatment side effects
Chapter 3 Key drug classes
- Key drug classifications
- Hormonals drug class
  - Leading hormonal drugs
- Chemotherapeutics drug class
  - Leading chemotherapeutic drugs
- Innovatives drug class
  - Leading innovative drugs
- Selected adjuncts drug class
  - Leading selected adjunct drugs
Chapter 4 Key products
- Leading products
- Top 10 leading cancer drugs
  - Rituxan/MabThera (rituximab)
  - Herceptin (trastuzumab)
  - Aranesp (darbepoetin alfa)
  - Avastin (bevacizumab)
  - Gleevec/Glivec (imatinib)
  - Neulasta (pegfilgrastim)
  - Eprex/Procrit (epoetin alfa)
  - Taxotere (docetaxel)
  - Epogen (epoetin alfa)
  - Eloxatin (oxaliplatin)
Chapter 5 Key companies
- Major cancer players
- Leading companies
  - Amgen
  - Roche
  - Novartis
  - Genentech
  - Sanofi-Aventis
  - AstraZeneca
  - Johnson & Johnson
  - Pfizer
  - Eli Lilly
  - Merck
Chapter 6 Key trends and opportunities
- Key disease market forecasts
  - Global markets
  - Cancer sites
- Key drug class forecasts
  - Hormonals
  - Chemotherapeutics
  - Innovatives
  - Selected adjuncts
- Key product forecasts
  - Rituxan/MabThera (rituximab)
  - Herceptin (trastuzumab)
  - Aranesp (darbepoetin alfa)
  - Avastin (bevacizumab)
  - Gleevec/Glivec (imatinib)
  - Neulasta (pegfilgrastim)
  - Eprex/Procrit (epoetin alfa)
  - Taxotere (docetaxel)
  - Epogen (epoetin alfa)
  - Eloxatin (oxaliplatin)
  - Forecast patent expiries
- Key company forecasts
  - Amgen
  - Roche
  - Novartis
  - Genentech
  - Sanofi-Aventis
  - AstraZeneca
  - Johnson & Johnson
  - Pfizer
  - Eli Lilly
  - Merck
Appendix
- Proprietary data sources
- Product Trends Database
- R&D Trends Database
- Company Trends Database
- Market Trends Database
List of Figures (Cancer Market Trends 2008 - 2012)
- Figure 1: Global cancer market, 2003-2007
- Figure 2: Report structure
- Figure 3: Disease burden in seven major pharmaceutical markets, 2007
- Figure 4: New cancer cases in the US, 2008
- Figure 5: Cancer deaths in the US, 2008
- Figure 6: Cancer epidemiology in seven major markets, 2007
- Figure 7: Prostate cancer epidemiology in seven major markets, 2007
- Figure 8: Breast cancer epidemiology in seven major markets, 2007
- Figure 9: Lung and bronchus cancer epidemiology in seven major markets, 2007
- Figure 10: Colorectal cancer epidemiology in seven major markets, 2007
- Figure 11: Urinary bladder cancer epidemiology in seven major markets, 2007
- Figure 12: Non-Hodgkin's lymphoma epidemiology in seven major markets, 2007
- Figure 13: Melanoma epidemiology in seven major markets, 2007
- Figure 14: Kidney and renal pelvis cancer epidemiology in seven major markets, 2007
- Figure 15: Leukemia epidemiology in seven major markets, 2007
- Figure 16: Uterine corpus/endometrium (uterus) cancer epidemiology in seven major markets, 2007
- Figure 17: Global cancer market by drug class, 2007
- Figure 18: Global cancer market by drug class, 2003-2007
- Figure 19: Global cancer market trends by drug class, 2006-2007
- Figure 20: Hormonals market, 2003-2007
- Figure 21: Leading hormonal drugs by approval date, 1985-2007
- Figure 22: Chemotherapeutics market, 2003-2007
- Figure 23: Leading chemotherapeutic drugs by approval date, 1991-2007
- Figure 24: Innovatives market, 2003-2007
- Figure 25: Leading innovative drugs by approval date, 1983-2007
- Figure 26: Selected adjuncts market, 2003-2007
- Figure 27: Leading selected adjunct drugs by approval date, 1988-2007
- Figure 28: Cancer blockbuster trends, 2006-2007
- Figure 29: Top 10 cancer products by global sales, 2007
- Figure 30: Top 10 companies by global cancer sales, 2007
- Figure 31: Top 10 companies by global cancer market share, 2007
- Figure 32: Top 10 companies by global cancer sales, 2006-2007
- Figure 33: Cancer incidence forecasts by geographic market, 2007-2012
- Figure 34: Cancer incidence forecasts by disease market, 2007-2012
- Figure 35: Global cancer market forecast, 2003-2012
- Figure 36: Global cancer market forecasts by drug class, 2003-2012
- Figure 37: Top 10 cancer drugs by forecast sales, 2012
- Figure 38: Rituxan/MabThera (rituximab) forecast sales, 2003-2012
- Figure 39: Herceptin (trastuzumab) forecast sales, 2003-2012
- Figure 40: Aranesp (darbepoetin alfa) forecast sales, 2003-2012
- Figure 41: Avastin (bevacizumab) forecast sales, 2004-2012
- Figure 42: Gleevec/Glivec (imatinib) forecast sales, 2003-2012
- Figure 43: Neulasta (pegfilgrastim) forecast sales, 2003-2012
- Figure 44: Eprex/Procrit (epoetin alfa) forecast sales, 2003-2012
- Figure 45: Taxotere (docetaxel) forecast sales, 2003-2012
- Figure 46: Epogen (epoetin alfa) forecast sales, 2003-2012
- Figure 47: Eloxatin (oxaliplatin) forecast sales, 2003-2012
- Figure 48: Forecast patent expiries by 2007 global sales, 2008-2017
- Figure 49: Top ten companies by cancer sales trends, 2007-2012
List of Tables (Caner Market Trends 2008 -2012
- Table 1: Global cancer market trends by drug class, 2005-2007
- Table 2: Leading hormonal drugs, 2007
- Table 3: Hormonals market trends, 2005-2007
- Table 4: Leading chemotherapeutic drugs, 2007
- Table 5: Chemotherapeutics market trends, 2005-2007
- Table 6: Leading innovative drugs, 2007
- Table 7: Innovatives market trends, 2005-2007
- Table 8: Leading selected adjunct drugs, 2007
- Table 9: Selected adjuncts market trends, 2005-2007
- Table 10: Top 20 cancer products by global sales, 2005-2007
- Table 11: Rituxan/MabThera (rituximab) profile, 2007
- Table 12: Herceptin (trastuzumab) profile, 2007
- Table 13: Aranesp (darbepoetin) profile, 2007
- Table 14: Avastin (bevacizumab) profile, 2007
- Table 15: Gleevec/Glivec (imatinib) profile, 2007
- Table 16: Neulasta (pegfilgrastim) profile, 2007
- Table 17: Eprex/Procrit (epoetin alfa) profile, 2007
- Table 18: Taxotere (docetaxel) profile, 2007
- Table 19: Epogen (epoetin alfa) profile, 2007
- Table 20: Eloxatin (oxaliplatin) profile, 2007
- Table 21: Top 10 companies by global cancer sales, 2005-2007
- Table 22: Amgen profile, 2007
- Table 23: Amgen cancer pipeline, 2007
- Table 24: Roche profile, 2007
- Table 25: Roche cancer pipeline, 2007
- Table 26: Novartis profile, 2007
- Table 27: Novartis cancer pipeline, 2007
- Table 28: Genentech profile, 2007
- Table 29: Genentech cancer pipeline, 2007
- Table 30: Sanofi-Aventis profile, 2007
- Table 31: Sanofi-Aventis cancer pipeline, 2007
- Table 32: AstraZeneca profile, 2007
- Table 33: AstraZeneca cancer pipeline, 2007
- Table 34: Johnson & Johnson profile, 2006
- Table 35: Johnson & Johnson cancer pipeline, 2007
- Table 36: Pfizer profile, 2007
- Table 37: Pfizer cancer pipeline, 2007
- Table 38: Eli Lilly profile, 2007
- Table 39: Eli Lilly cancer pipeline, 2007
- Table 40: Merck profile, 2007
- Table 41: Merck cancer pipeline, 2007
- Table 42: Global cancer market forecasts by drug class, 2005-2012
- Table 43: Top 10 cancer drugs forecasts, 2005-2012
- Table 44: Top 10 companies by cancer sales forecasts, 2007-2012
- Table 45: Top 56 cancer products by global pharmaceutical sales, 2005-2007
- Table 46: Top 14 companies by global cancer sales, 2005-2007